ProCE Banner Activity

TROPiCS-02: OS With Sacituzumab Govitecan vs Treatment of Physician’s Choice for HR+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
Results from the phase III TROPiCS-02 study showed that sacituzumab govitecan improved OS compared with physician’s choice of single-agent chemotherapy in patients with previously treated HR+/HER2- advanced breast cancer.Results from the phase III TROPiCS-02 study showed that sacituzumab govitecan improved OS compared with physician’s choice of single-agent chemotherapy in patients with previously treated HR+/HER2- advanced breast cancer.

Released: September 13, 2022

Expiration: September 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.